GURUFOCUS.COM » STOCK LIST » USA » NYSE » Johnson & Johnson (NYSE:JNJ) » Definitions » Debt-to-Equity
Switch to:

Johnson & Johnson Debt-to-Equity

: 0.43 (As of Jun. 2022)
View and export this data going back to 1944. Start your Free Trial

Johnson & Johnson's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $4,305 Mil. Johnson & Johnson's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $28,292 Mil. Johnson & Johnson's Total Stockholders Equity for the quarter that ended in Jun. 2022 was $76,357 Mil. Johnson & Johnson's debt to equity for the quarter that ended in Jun. 2022 was 0.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Johnson & Johnson's Debt-to-Equity or its related term are showing as below:

JNJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06   Med: 0.28   Max: 0.59
Current: 0.43

During the past 13 years, the highest Debt-to-Equity Ratio of Johnson & Johnson was 0.59. The lowest was 0.06. And the median was 0.28.

JNJ's Debt-to-Equity is ranked worse than
60.56% of 857 companies
in the Drug Manufacturers industry
Industry Median: 0.30 vs JNJ: 0.43

Johnson & Johnson Debt-to-Equity Historical Data

The historical data trend for Johnson & Johnson's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.51 0.47 0.56 0.46

Johnson & Johnson Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.48 0.46 0.44 0.43

Competitive Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Johnson & Johnson Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Debt-to-Equity falls into.



Johnson & Johnson Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Johnson & Johnson's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Johnson & Johnson's Debt to Equity Ratio for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson  (NYSE:JNJ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Johnson & Johnson Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson Business Description

Johnson & Johnson logo
Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.
Executives
Adamczyk Darius director 855 S. MINT STREET CHARLOTTE NC 28202
Hait William officer: See Remarks ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mammen Mathai officer: EVP, Pharm, R&D THERAVANCE,INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Broadhurst Vanessa officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Swanson James D. officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
West Nadja director 1915 REXFORD ROAD CHARLOTTE NC 28211
Decker Robert J officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Joly Hubert director C/O BEST BUY CO, INC. 7601 PENN AVENUE SOUTH RICHFIELD MN 55423
Weinberger Mark A director METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166
Hewson Marillyn A director C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662
Mongon Thibaut officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wengel Kathryn E officer: EVP, Chief GSC Officer JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wolk Joseph J officer: Exec VP, CFO JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mcevoy Ashley officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Taubert Jennifer L officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933

Johnson & Johnson Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)